3D Systems Announces the Appointment of the Honorable Alex M. Azar II to its Medical Advisory Board

0

3D Systems Inc.

Secretary Alex Azar

Secretary Alex Azar

Secretary Alex Azar

ROCK HILL, South Carolina, Aug. 08, 2022 (GLOBE NEWSWIRE) — 3D systems (NYSE: DDD) today announced the appointment of Alex M. Azar II, former U.S. Secretary of Health and Human Services, as the third member of the company’s newly created Medical Advisory Board (MAB). Secretary Azar will join Dr. Stephen Klasko, former President and CEO of Thomas Jefferson University and Jefferson Health, and Dr. David Shulkin, former U.S. Secretary of Veterans Affairs, as members of MAB, whose mission primary focus is to provide strategic input, advice and recommendations for the company’s growing efforts in regenerative medicine.

Secretary Azar is a globally recognized leader in healthcare, having built a distinguished track record of success in both the public and private sectors. His leadership roles include President of the U.S. Division of Eli Lilly and Company, one of the world’s largest and most successful healthcare companies, and a recognized leader in the discovery, development and commercialization of pharmaceutical products that have improved the lives of countless people around the world. Along with his leadership role at Eli Lilly, Secretary Azar also served on the board of directors of the Biotechnology Innovation Organization (BIO), the world’s largest advocacy organization representing the biotechnology industry.

In addition to his leadership in the private sector, Secretary Azar also has a long and distinguished career in public service. He was appointed General Counsel for the US Department of Health and Human Services (HHS) in 2001, unanimously confirmed by the US Senate. After four years of distinguished service as General Counsel, he was appointed Assistant Secretary of HHS and was again unanimously confirmed by the Senate. Based on his exceptional experience and success in these roles, Secretary Azar was later appointed and confirmed as the 24e US Secretary of Health and Human Services. With responsibility for overseeing essential public health organizations such as the Center for Disease Control and Prevention, the Food and Drug Administration, and the Centers for Medicare and Medicaid Services, Secretary Azar was a recognized champion for improving the health and well-being of all Americans, ranging from the accessibility and safety of health care to the effective use of new medical technologies to improve patient outcomes and reduce the cost of care. Among Secretary Azar’s many accomplishments as Secretary of HHS was his role as one of the architects of Operation Warp Speed, a public-private partnership initiated by the U.S. government that dramatically accelerated the development and manufacturing multiple highly effective COVID-19 vaccines and therapeutics. which have proven essential to the global effort to combat the COVID-19 pandemic.

Commenting on Secretary Azar’s appointment, Dr. Jeffrey Graves, President and CEO of 3D Systems, said, “We are honored and excited to have Secretary Azar join our Medical Advisory Board. As a recognized champion of innovation in pharmaceuticals and medical devices, he will be a tremendous resource in advancing our efforts in regenerative medicine. With the rapid progress we are making in our ability to print vascularized human tissue, we are entering an exciting phase of demonstrating efficacy in a wide range of human organ and non-organ applications, and for use in drug discovery where the goal is to shorten the time to market for new drug therapies and reduce reliance on animal testing. With his unique experience in each of these key areas, I am confident Secretary Azar’s contributions will have a significant impact.

Commenting on his appointment, Secretary Azar said, “Technological innovation has the ability to dramatically improve health care outcomes, and 3D Systems’ efforts in regenerative medicine hold the potential to improve lives in ways that was hard to imagine just a few years ago. I am honored and excited to have this opportunity to advise the company as it pushes the boundaries of healthcare innovation and builds a world-class regenerative medicine business.

Forward-looking statements
Certain statements made in this release that are not statements of historical or current fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors. which may cause the company’s actual results, performance or achievements to be materially different from historical results or any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by words such as “believes”, “believes”, “expects”, “may”, “will”, “estimates”, “intends”. , “anticipate” or “plan” or the negative of these terms or other comparable terms. Forward-looking statements are based on management’s current beliefs, assumptions and expectations and may include comments about the company’s beliefs and expectations regarding future events and trends affecting its business and are necessarily subject to uncertainties, including many are beyond the company’s control. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or anticipated in the forward-looking statements. research statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, the forward-looking statements are not and should not be taken as guarantees of future performance or results, and they will not necessarily prove to be precise indications. the times at which these performances or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by or on behalf of management, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law. requires it.

About 3D Systems
Over 35 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading additive manufacturing solutions partner, we bring innovation, performance and reliability to every interaction – enabling our customers to create products and business models never before possible. With our unique offering of hardware, software, materials and services, each application-specific solution is powered by the expertise of our application engineers who work with customers to transform the way they deliver their products and services. 3D Systems’ solutions serve a variety of advanced applications in healthcare and industrial markets such as medical and dental, aerospace and defense, automotive, and durable goods. More information about the company is available at www.3dsystems.com.

A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8da76fb4-c498-4397-9355-d3c0c893b492

Share.

Comments are closed.